Compare Anheuser-Busch Inbev SA (BUD) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Ginkgo Bioworks Holdings Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.76 (market cap $153.45B), while Ginkgo Bioworks Holdings Inc trades at $9.1 (market cap $590.53M). The key difference: Anheuser-Busch Inbev SA is far larger — about 259.9× Ginkgo Bioworks Holdings Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| BUD | DNA | |
|---|---|---|
Market Cap | $153.45B | $590.53M |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $16.14 |
52-Week Low | $57.10 | $5.48 |
Enterprise Value | $214.64B | $627.78M |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
